Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
DNA vaccines against COVID-19: Perspectives and challenges

Marcelle Moura Silveira a,b,c, Gustavo Marçal Schmidt Garcia Moreira b,c, Marcelo Mendonça c

a Faculty Anhanguera, Department of Pharmacy, Pelotas, Rio Grande do Sul, Brazil
b Institut für Biochemie, Biotechnologie und Bioinformatik, Technische Universität Braunschweig, Braunschweig, Germany
c Federal University of Agreste of Pernambuco, Veterinary Medicine Course, Garanhuns, Pernambuco, Brazil

ARTICLE INFO

Keywords: Immunization DNA vaccine Nucleic acid-based vaccines Coronavirus COVID-19

ABSTRACT

The coronavirus disease 2019 (COVID-19) is caused by a novel coronavirus known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is associated with several fatal cases worldwide. The rapid spread of this pathogen and the increasing number of cases highlight the urgent development of vaccines. Among the technologies available for vaccine development, DNA vaccination is a promising alternative to conventional vaccines. Since its discovery in the 1990s, it has been of great interest because of its ability to elicit both humoral and cellular immune responses while showing relevant advantages regarding producibility, stability, and storage. This review aimed to summarize the current knowledge and advancements on DNA vaccines against COVID-19, particularly those in clinical trials.

1. Introduction

In the second week of December 2019, patients with an atypical form of pneumonia were diagnosed in Wuhan, Hubei Province, China [1]. At this time, it was detected as a new coronavirus, initially named nCoV-2019. In mid-January, the genome of this pathogen was made public, with its precise definition as “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2), thus named “coronavirus disease 2019” (COVID-19). This virus has spread rapidly across mainland China and worldwide. On March 11, the World Health Organization declared a pandemic state to the whole world [2–5].

Coronaviruses are a large family of viruses known to cause illnesses in different animals, ranging from the common cold to more severe diseases. As of this year, seven different coronaviruses from alpha and beta genera are known to infect and cause disease in humans. These include the betacoronaviruses that cause severe acute respiratory syndrome (SARS-CoV), the Middle East respiratory syndrome (MERS-CoV) [3], and SARS-CoV-2, all of which were responsible for a relatively high number of cases with high mortality rates. As of mid-August 2020, COVID-19 has already been responsible for more than 20 million infections and 750 thousand deaths [2]. As transmission rates are shown to be higher than other coronaviruses, SARS-CoV-2 is considered a concern for public health, mainly because of the possibility of overloading intensive care units, thus causing health systems to collapse.

Considering this upcoming threat, the majority of countries adopted measures to reduce the transmission rate, which reduced the burden of COVID-19, though causing a significant economic loss globally. Therefore, the search for a vaccine against SARS-CoV-2 was the main topic of research in the world to help restabilize the normal pace [6]. However, no coronavirus vaccine to prevent respiratory infections in humans has been licensed yet [7].

In this context, various groups have made remarkable advances in developing new vaccines in a very short time [8]. Traditional vaccine development methods, although extremely effective in combating highly contagious diseases such as measles, require a large number of active viruses during production and can even take a longer time for the development in case attenuated pathogens are needed. Thus, more advanced vaccine technologies, such as DNA, RNA, subunit, and virus-like particles, have been extensively tested [9]. The aim of this study was to elucidate the current knowledge and discuss the use of DNA vaccines against COVID-19.

2. Vaccine development during the SARS-CoV-2 pandemic

For human vaccine development, regulatory agencies of different countries have historically requested an increasing number of clinical studies with a large number of patients and complexity. These measures assure that the final vaccine product will be safe and effective for
different population subgroups before licensure for commercial use. Typically, 10–15 years are required from conducting preclinical studies to obtaining vaccine licensure. The fastest approval, though, was the Ebola vaccine, which took five years [10].

In brief, clinical tests in humans can be divided into four phases: phase 1, wherein the vaccine is given to the healthy volunteers, and its safety and dosing are determined; phase 2, wherein initial immune stimulation is evaluated, and safety is further explored in small numbers of healthy people; phase 3 wherein the vaccine efficacy in preventing the disease is determined after it is given to a large cohort; and phase 4 which is conducted after vaccine approval to guarantee its safety and study long-term effects [11]. The necessity of these phases is unanimous in the vaccinology field. However, the time required for each of these steps needs to be better planned to fasten the process and obtain the approval of a vaccine during a pandemic situation.

The vast majority of viral vaccines currently licensed for humans can be categorized as virus or protein based. The virus-based group consists of an inactivated or live-attenuated virus, and even though these vaccines are more immunogenic, several limitations are associated with these approaches. In the case of SARS-CoV-2, large quantities of viruses need to be produced under biosafety level 3 conditions for an inactivated vaccine, and extensive safety testing is required to ensure they do not revert to infective [12]. In contrast, subunit vaccines such as those with purified proteins present higher safety and scalability than whole-pathogen vaccines. Nevertheless, they may show less immunogenicity and require multiple immunizations [13,14].

The current life-threatening infectious diseases, such as influenza (H5N1 subtype), Zika, Ebola, and MERS-CoV, are driving the demand for new, faster, and effective vaccine platforms [15,16]. Considering recent experiences from the SARS-CoV-2 pandemic, next-generation platforms must allow having a vaccine formulation useful for clinical trials in less than 16 weeks from genome sequencing to application in humans. Furthermore, these technologies elicit consistent immune responses across different pathogens and are suitable for large-scale manufacturing even as a pathogen-agnostic platform. Multiple approaches are still under development; however, the DNA- and RNA-based approaches are among those with the greatest potential for speeding up the production of effective vaccines when urgently needed [12,17].

On August 11, 2020, Russia was the first country to approve a vaccine against COVID-19 named “Sputnik V,” formerly known as the “Gam-COVID-Vac,” which is based on a viral vector technology. However, the world scientific community has raised doubts about its clinical trials to prove its safety and efficacy [11]. Although there is a consensus that developing a safe and effective vaccine against SARS-CoV-2 is crucial to end the COVID-19 pandemic, cautious measures are necessary to ensure that new vaccines are safe for the entire population [18]. In addition, efficacy and safety are not the only crucial criteria, as a vaccine candidate must also have scalable production. Thus, it is necessary to select an adequate vaccine platform for accelerating vaccine development.

### 3. DNA vaccine

Immunization with nucleic acids has received considerable attention in the field of new generation vaccines. The first proof of concept of a DNA vaccine was made in 1990 and involved the injection of RNA or DNA molecules, expressing chloramphenicol acetyltransferase, luciferase, and beta-galactosidase into mouse skeletal muscle, and the expression of reporter genes in vivo, which can be detected for up to two months after infection [19,20]. In brief, DNA vaccine consists of delivering genes or fragments of it, encoding immunogenic antigens to the host’s cells by using DNA plasmids as a vector. This approach induces both humoral and cell-mediated immune responses efficiently [21,22]. The vaccine formulation is made such that the genetic material is translocated to the host’s cell nucleus (Fig. 1). Once it reaches there, the mammalian promoter present in the vector structure is activated, triggering the transcription of the gene used for the vaccine through the

---

**Fig. 1.** Induction of cellular and humoral immunity after immunization with DNA vaccines. A DNA vaccine consists of a plasmid produced in bacteria that encodes the protein of interest (an antigen) in the presence of a mammalian promoter. It is placed in a way that it reaches the cell nucleus, enabling the transcription and translation in the transfected human cells (step 1). After the plasmid uptake in vivo, the encoded protein is expressed in the host’s cells, and the vaccine antigen can be then presented to antigen-presenting cells (APCs), such as dendritic cells (DCs), through the major histocompatibility complex (MHC) pathways and be presented to activate naïve T cells. CD8+ T cell immunity is predominantly activated by endogenously expressed antigens presented on MHC class I molecules (step 2a). The active CD8+ T cell stimulates the release of cytokines (e.g., interferon-gamma [IFN-γ] and tumor necrosis factor-alpha [TNF-α]) that inhibit viral replication and increase the expression of MHC I molecules. Therefore, macrophages are also activated to support cell-mediated immune responses (step 2b). However, CD4+ T helper cell activation is triggered through MHC class II from APC (step 3). In case the vaccine proteins are secreted, these targets are recognized by B cell receptors in naïve B cells, which also use MHC-II to get activated (step 4). In this immune pathway, activated B cells will produce different classes of antibodies (mainly IgG) to protect against the disease (step 5). Furthermore, immunization with DNA vaccine expresses proinflammatory cytokines and chemokines. DGs are responsible for producing IL-10, IL-12, and TNF-α that induce the cellular response by activating CD8+ T and IL-4 is involved in activating CD4+ T.
host’s cellular machinery. The antigen-presenting cells (APCs) are the major target cells to receive the genetic material. In addition, myocytes have been reported to play a crucial role [19]. After the translation of the translocated gene into a protein or protein fragment, it is further processed into peptides that bind to major histocompatibility complex (MHC) class I or II. Cells other than APC, such as the myocytes, use MHC-I for the antigen presentation, and APC, such as dendritic cells (DCs), can use MHC-II, resulting in cross-priming and presentation of antigens to both CD4+ and CD8+ T cells [23–26]. Regarding COVID-19 immune regulation, a recent study showed that at-risk patients with pericardial effusion with a worse prognosis show elevated CD3+CD8+ T cells together with reduced Tregs and CD14+HLA-DR+ monocytes [36]. These findings show that the main course of the disease occurs because of a misbalance of the immune response, often leading to misregulation and worsening of the infection [27]. Thus, the vaccines in development against COVID-19 aim to build a proper and effective immune response without causing such misbalance. Of note, not only this cellular immune response can be activated, but also humoral responses can be triggered if the produced immunogen is released from the cells and recognized by B cell receptors [25].

In addition, intrinsic elements of plasmid DNA, such as CpG unmethylated sequences, can activate innate immune responses, thereby enhancing adaptive immune responses against the expressed antigens. Although clinical trials using DNA vaccines in humans induced both cellular and humoral responses, these responses are often not sufficient to elicit significant clinical benefits. Therefore, DNA vaccines have only been licensed for use in veterinary medicine [21,24,25]. Because of this limitation, several research lines focus on DNA vaccine optimization and delivery, including promoter design, codon optimization, adjuvants, use of electroporation, prime/boost immunization, or “omics” approaches for refined vaccine design [28].

Compared with traditional live or attenuated vaccines, DNA vaccines have several advantages, such as induction of broad immune responses without any risk being associated with replicating microorganisms; stimulation of both cellular and humoral immunity; construction of a vector encoding different antigens in a single vaccine; efficient large-scale, low-cost, production; and high storage stability [21,29]. In the vaccinology field, storage is a crucial factor, as preserving the high quality of the vaccine contents and, thus, the protective potential is necessary. Hence, cold storage is essential to ensure the survival of live vaccines and preserve their content. On the other hand, DNA vaccines are highly stable and have less need for refrigeration, which may be highly practical for use in endemic areas [23].

4. SARS-CoV-2

The SARS-CoV-2 has a single-stranded, positive-sense RNA genome with approximately 26–32 kilobases in size. This virus belongs to the family Coronaviridae (order Nidovirales). The Coronaviridae family contains four genera to include alphacoronavirus (alphaCoV), betacoronavirus (betaCoV), deltacoronavirus (deltaCoV), and gammacoronavirus (gammaCoV). Although bats and rodents are the common colds [31]. It has been reported that betaCoV used 9-O-acetylsialic acids as a receptor and alphaCoV used host proteins, including polyisoprimeulin tract binding and hNRP-A1 as receptors [31].

In addition to these common cold viruses, the three CoVs responsible for high mortality rates in humans, i.e., MERS-CoV, SARS-CoV, and SARS-CoV-2, are from betaCoV genus. The genome sequencing of SARS-CoV-2 has shown an overall similarity of 98% with the bat CoV RaTG13 [32]. Moreover, SARS-CoV-2 can enter the host’s cells through different mechanisms, including an endosomal and nonendosomal entry through the action of proteases. Currently, the main receptor for SARS-CoV-2 entry in humans is angiotensin-converting enzyme 2 (ACE2), which is also used by SARS-CoV [32–35].

Structurally, SARS-CoV-2 contains four structural proteins, including spike (S), envelope (E), membrane (M), and nucleocapsid (N). Moreover, these proteins share high sequence similarity to those from SARS-CoV and MERS-CoV [32]. Thus, the knowledge from SARS-CoV and MERS-CoV vaccines provides some insights and lessons concerning the development of SARS-CoV-2 vaccine design and thus helps in accelerating the development of new vaccines for COVID-19 [18]. Some successful DNA vaccines expressing S, M, and N proteins have been developed against SARS-CoV. The obtained results confirmed the strong protective humoral and cellular immune responses in mice, macaques, and camels [36–40]. Furthermore, the first DNA vaccine candidate against MERS-CoV to enter clinical trials, named GLS-S300, was well tolerated with no vaccine-associated serious adverse events. Immune responses were dose-independent, detected in more than 85% of participants after two immunization regimens, and durable through one year of follow-up [41,42].

5. The immune response and COVID-19

The immune system can be categorized into innate immunity (rapid and nonspecific response) and adaptive immunity (slow and specific response). The adaptive immunity can be further divided into cellular responses mainly characterized by T cell maturation and humoral responses characterized by B cell maturation. Considering this, vaccines are prepared to induce both arms of the adaptive immune system and stimulate a sufficient number of memory T and B cells. Furthermore, immunity can be divided into two types: active and passive. Active immunity refers to the process of exposing a patient to an antigen to generate an adaptive immune response, and passive immunity refers to the transfer of antibodies from one individual to another [43].

Moreover, passive immunity can occur naturally when maternal antibodies are transferred to the fetus through the placenta or from breast milk to the gut of the infant [43,44]. Regarding immunity against COVID-19, it is still not completely clear, which responses occur in natural COVID-19, and if people who recover from COVID-19 infection are protected from a second infection [45,46].

SARS-CoV-2 is associated with a robust adaptive immune response of both T and B cells. In addition, both immunoglobulin (Ig)M and IgG antibodies are produced mainly against N and S proteins. The antibodies appear around the 10th day of infection, and most patients seroconvert within three weeks. If reinfections occur, it would indicate that immune response against SARS-CoV-2 is not protective and, therefore, the use of vaccines could not be associated with protection [47].

On the other hand, SARS-CoV-2 antibodies are found to be protective, although it remains uncertain if a high level of circulating antibodies lasts for enough duration to avoid further infections. This question still cannot be properly answered, as SARS-CoV-2 has been in the community only for the past few months. However, results obtained with other closely related coronaviruses, mainly SARS-CoV and MERS-CoV, showed robust, long-lasting T and B cell immune responses [48–50].

6. DNA vaccine in clinical trials

As of January 2020, the complete genome of SARS-CoV-2 was published. Understanding the genome structure of the virus is a critical step for the development of new vaccines [33,34]. During infection, antibodies are raised mainly against both N and S proteins. The N protein covers the viral genome and is also involved in the release of virus particles from cells. Whereas the S protein plays a significant role in pathogenesis by binding to the host cell through its receptor-binding domain and thus initiating the infection to the host cell [52]. The S
protein has 1273 amino acid residues and can be divided into three subunits, S1, S2, and S2’, each having a different role during the adherence to the host cell [52].

The S1 subunit is involved in the attachment of virions to the host cell membrane by interacting with human ACE2, which initiates the infection process. Furthermore, during this process, the S protein undergoes conformational changes induced by its entry into the endosomes of the host’s cell. The S2 subunit acts as a fusion protein that helps in the union of the viral and host cell membranes [53,54]. During the fusion process, the S2 protein appears in three consecutive conformational states: 1) prefusion (native state), 2) prehairpin (intermediate state), and 3) ensuing postfusion (hairpin state). Subsequently, surface proteases cleave S2. SARS-CoV-2 S protein has a furin site as an additional cleavage spot, which may be associated with the broader infectivity in comparison with SARS-CoV [55]. Understanding these dynamic conformation states that are associated with the mechanism of viral entry into the host cell membrane could lead to the development of effective therapeutics [32,56].

The S protein has been used as the antigen of all DNA vaccines currently being tested in clinical trials (Table 1). One of them, named AG0301-COVID19 (ClinicalTrials.gov number, NCT04463472), uses a two-immunization scheme, the first with a low dose (1.0 mg) and the second with a high dose (2.0 mg). Both injections are administered intramuscularly within a two-week interval. At present, healthy individuals aged between 20 and 65 years are being recruited to evaluate the immunogenicity of this vaccine.

The biotechnology company (Inovio Pharmaceuticals, Plymouth Meeting, PA, USA) has previously developed experimental vaccines against MERS-CoV (INO-4700) and is currently evaluating a DNA vaccine against COVID-19. A plasmid pGIX9501 designed to encode the S protein of SARS-CoV-2 has been used as an antigen. The INO-4800 vaccine induced both cellular and humoral immune responses that were observed within days following a single immunization in mice and guinea pigs during preclinical testing [57].

Therefore, the company started a phase 1, open-label study to evaluate the safety, tolerability, and immunogenicity of INO-4800. This vaccine is administered intradermally through electroporation [41,57]. Moreover, a preliminary study showed that INO-4800 induced neutralizing antibodies that blocked the binding of SARS-CoV-2 S protein to the host receptor ACE2 [57].

Electroporation uses short electrical pulses at the vaccine application site, resulting in an increased cell membrane permeability; improved absorption of the antigen; and, consequently, a more effective immune response [58]. Moreover, electroporation was associated with an enhancement of immune response by recruiting inflammatory cells and APCs to the application site [59].

Vaccine vectors have several advantages: low cost, noninvasive administration, and high safety levels [60]. The bacTRL-Spike vaccine uses live, recombinant Bifidobacterium longum that contains synthetic plasmid DNA encoding the S protein of SARS-CoV-2. Bifidobacterium is a nonpathogenic anaerobic bacterium that is part of the human microbiota. In addition, it has been proposed that this bacterium improves the host’s endurance by increasing the immune response against viral infection [61].

Some strains of Bifidobacterium were tested as carriers of antigens for its use as a recombinant vaccine against hepatitis C virus, enterovirus, and cancer [60,62,63]. A clinical trial was designed to evaluate the safety and tolerability of orally immunized bacTRL-Spike vaccine in healthy adults. However, this study has not yet started recruiting, and the estimated completion date is December 31, 2021 (ClinicalTrials.gov number, NCT04334980). Moreover, the safety and immunogenicity of GX-19, another DNA vaccine against COVID-19 that uses intramuscular immunizations are already in clinical trials.

7. mRNA vaccines: a fast and consistent strategy to control COVID-19

Over the past decade, major technological innovation and research investment have enabled mRNA to become a promising therapeutic tool in the fields of vaccine development. At present, multiple mRNA vaccine

| Study start date/ study identifier | Technology | Study phase/ ECD | Project title | Immunogen | Via | Subjects | Number of subjects | Study location |
|----------------------------------|------------|-----------------|--------------|-----------|-----|----------|-------------------|---------------|
| June 27, 2020/ NCT04445389       | DNA vaccine | Phase 1–2       | Safety and Immunogenicity Study of GX-19, a COVID-19 Preventive DNA Vaccine in Healthy Adults | S protein | IM  | Adults (18–50 years old) | 210 | Korea           |
| July 29, 2020/ NCT04463472       | DNA vaccine | Phase 1–2       | Study of COVID-19 DNA Vaccine (AG0301-COVID19) | S protein | IM  | Adults (20–65 years old) | 30  | Japan           |
| August 31, 2020/ NCT04527081     | DNA vaccine | Phase 1–2       | Study of COVID-19 DNA Vaccine (AG0302-COVID19) | S protein | IM  | Adults (20–65 years old) | 30  | Japan           |
| April 3, 2020/ NCT04334980       | DNA vaccine | Phase 1         | Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers | S protein | ID (EP) | Adults (18 years and older) | 120 | United States   |
| July 2020/ NCT04334980          | DNA vaccine | Phase 1         | Evaluating the Safety, Tolerability and Immunogenicity of bacTRL-Spike Vaccine for Prevention of COVID-19 | S protein | oral | Adults (18 years and older) | 72  | Canada          |
| November 2020/ NCT04591184      | DNA vaccine | Phase 1         | A Clinical Trial of a Plasmid DNA Vaccine for COVID-19 (Covigenta VAX-001) in Adults | S protein | IM  | Adults (18 to 84 years old) | 30,000 | United States |
| March 16, 2020/ NCT04470427     | mRNA vaccine | Phase 2         | Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19) | S protein | IM  | Adults (18 to 99 years old) | 691 | Germany         |
| June 18, 2020/ NCT04515147      | mRNA vaccine | Phase 2         | A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults | S protein | IM  | Adults (18–60 years old) | 2481 | Germany         |
| April 23, 2020/ NCT04368728     | mRNA vaccine | Phase 2–3       | A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-19 in Healthy Adults | S protein | IM  | Adults (18–85 years old) | 96  | Thailand        |
| January 2021/ NCT04566276       | mRNA vaccine | Phase 1         | Safety and Immunogenicity Study of INO-4800 for COVID-19 in Healthy Volunteers | S protein | ID (EP) | Adults (18–75 years old) | 96  | Thailand        |

ECD, Estimated Study Completion Date; IM, intramuscular; EP, electroporation; ID, intradermal.

C. Bifidobacterium longum.

L. Lipid nanoparticle-encapsulated mRNA.
platforms against infectious diseases and several types of cancer have demonstrated encouraging results in both animal models and humans. Moreover, the area of mRNA vaccine is very rapidly developing. The mRNA vaccine does not need to reach the cell nucleus like the DNA ones, which is one of the potential practical advantages [64]. Thus, the mode of application and effectiveness of mRNA vaccines may be increased [65]. In fact, several preclinical studies and human clinical trials are using mRNA technology, particularly during the SARS-CoV-2 pandemic [66,67].

The mRNA-based vaccines comprise mRNA that encodes a protein antigen. Although RNA is known to be a relatively unstable molecule, novel vaccine designs were developed to improve its stability and protein translation efficiency, which enhanced immune response. The mRNA-1273 (Moderna Inc. Cambridge, MA, USA) was the first mRNA vaccine to be designed against COVID-19 and has achieved a time record of 63 days from vaccine design to human trials. Phase 1 clinical trials in the USA were already published, whereas phases 2 and 3 are either analyzing results or ongoing (ClinicalTrials.gov number, NCT04470427). This vaccine uses lipid nanoparticle (LNP)-encapsulated mRNA that encodes for a full-length, prefusion stabilized S protein of SARS-CoV-2 [68–70].

Previous studies with similar formulations have demonstrated that the delivery of the mRNA vaccine has been optimized by using LNPs for intramuscular or intradermal administration [71,72]. Data showed that mRNA-1273 induced both potent neutralizing antibody and CD8 T cell responses. In addition, it protected against SARS-CoV-2 infection in the lungs and nose of mice without evidence of immunopathology [73,74].

The mRNA-1273 vaccine is currently in phase 3 clinical trial. A preliminary report published after phase 1 showed that the vaccine-induced anti-SARS-CoV-2 immune responses in 45 participants. Antibody responses were increased with a higher dose (250 μg) after the first vaccination. Moreover, after the second vaccination, neutralizing antibodies were detected in all evaluated participants, with generally similar values to those in the upper half of the distribution of a panel of control convalescent serum specimens. Adverse events such as fatigue, chills, headache, myalgia, and pain at the injection site occurred in more than half of the participants. Moreover, systemic adverse events were more common after the second vaccination, particularly with the highest dose [73,75]. Another mRNA vaccine, called CVnCoV (ClinicalTrials.gov number, NCT04515147), encoding the full-length S protein and formulated with LNPs is recruiting volunteers (as of August 2020).

Another mRNA vaccine, the BNT162 (BioNTech, Mainz, Germany) is in advanced clinical trials and has four variants, namely, a1, b1, b2, and c2. It is another LNP mRNA vaccine that recently made the results of the phase 1/2 trial public but not yet peer reviewed [76]. In this study, only the BNT162b1 variant was tested in a prime-boost regimen within 21 days in three different doses [77]. Similar to mRNA-1273, the adverse events were dose-dependent and only mild to moderate, while the immune response showed a high level of neutralizing antibodies. Overall, these data suggest the potential to develop DNA and mRNA vaccines that are easier to design and can quickly proceed into clinical trials, which will be helpful for pandemic states such as the one caused by COVID-19 [77].

8. Nucleic acid-based vaccines and SARS-CoV-2

Immuninformatics is a branch of bioinformatics used to design vaccines against several infectious diseases [78–80]. This approach involves computational analysis of immunological data by predicting appropriate antigens, epitopes, carriers, and adjuvants for vaccine development. Therefore, immuninformatics can reduce the time and cost of vaccines [81,82]. Considering this, the design of novel multiple epitope mRNA vaccines consisting of cytotoxic T lymphocyte, helper T lymphocyte, and linear B lymphocyte epitopes derived from SARS-CoV-2 S protein, as well as adjuvant highly immunogenic, have been analyzed [53,81,83–85].

Furthermore, different DNA vaccine candidates expressing different forms of the SARS-CoV-2 S protein have been evaluated in 35 rhesus macaques. Vaccinated animals developed humoral and cellular immune responses, including neutralizing antibody titers that are comparable to those found in convalescent humans [86]. From a general perspective, although mRNA vaccines quickly advanced to clinical trials in humans, the majority of candidate DNA vaccines are currently in the preclinical stage.

9. Considerations and challenges

COVID-19 is an unusual global health threat wherein the vaccine is needed immediately. Because of the high risk of collapsing healthcare systems in several countries, governments had to implement lockdown measures, including no international travel and other public containment measures in attempting to reduce the virus morbidity and mortality worldwide [87–89]. Although effective, these actions led to vast economic devastation.

Until date, there is no effective drug to reduce the infection and pandemic burden [90,91]. However, exceptional efforts have been made in attempting to develop an effective and safe vaccine at the earliest, which should be available to all countries affected by the pandemic at an affordable price [92,93]. Previous advancements made since the SARS and MERS outbreaks have accelerated our understanding of the epidemiology, pathogenesis, and diagnosis of SARS-CoV-2, as well as the development of therapies to treat viral infection and possible vaccines [68].

In this pandemic situation, it is crucial to ensure that rigorous and adequate clinical trials are performed to evaluate drugs with antiviral effects for avoiding the usage of ineffective and unsafe drugs [68]. Current clinical trials of candidate vaccines are undergoing phase 1 or parallel 1/2 studies to initiate phase 3 at the earliest and decrease the time required for the development of the new vaccine [74].

Although advances in genetic sequencing and other technological developments have sped up the establishment of various vaccine platforms, several uncertainties still remain. Questions have arisen regarding the mutation rates of SARS-CoV-2, which could lead to immune evasion. Understanding mutations in the coding and non-coding regions, genetic diversity, pathogenicity, and host-pathogen interactions is essential. Mutations in the S protein seem to induce conformational changes, which may alter antigenicity and, thus, may affect the vaccine design [32,94,95]. Moreover, previous studies suggested that various mutations in the target proteins of the coronaviruses can be associated with drug resistance and changes in the protein structures of target proteins that may lead to vaccine inefficacy [32].

It is crucial to highlight that the uncertainty over long-lasting protection against COVID-19 still remains. Patients with reinfection have been reported, and it is necessary to determine how long a protective immune response can be maintained in an individual [96,97]. Considering the immunogenicity of the SARS-CoV-2 mRNA-1273 vaccine in older adults, it has been reported that after the second immunization, serum neutralizing activity was detected in all the participants, and binding and neutralizing antibody responses appeared to be similar to those described among vaccine recipients between the ages of 18 and 55 years and were above the median of a panel of control individuals who had donated convalescent serum [98]. Ideally, vaccination would induce long-lived immunity, but annual vaccination would be feasible based on experiences with the annual influenza vaccine [12].

In the current pandemic, several specialists have suggested that immune responses against SARS-CoV-2 could lead to antibody-dependent enhancement (ADE) [99]. Although this phenomenon has major importance for Flaviviruses and some feline coronaviruses, SARS-CoV and SARS-CoV-2 have shown not to cause this effect in living animals or humans [100]. However, if ADE becomes crucial during the current pandemic, both DNA- and RNA-based platforms could quickly provide alternatives to circumvent such issues, as regions or motifs of
the vaccine antigen responsible for causing ADE could be easily engineered or removed [101].

The great advantage of the current advancements in nucleic acid-based technologies for vaccine development is the short time required from the design to clinical trials. Therefore, it may be soon possible to test together, in the same vaccine, different variants of antigens that cover circulating mutations. This would represent a major step forward in vaccine development against rapidly emerging threats such as the current SARS-CoV-2 pandemic. Therefore, developing vaccines against COVID-19 require further studies on gene mutations and how to avoid vaccine failure because of them.

Declaration of competing interest

The authors have declared no conflict of interest.

References

[1] Ghaebi M, Osali A, Valizadeh H, Roshangar L, Almadri M. Vaccine development and therapeutic design for 2019-nCoV/SARS-CoV-2: challenges and chances. J. Cell. Physiol.. 2020.

[2] Bhagawathula AS, Almdalei WA, Rovetta A, Rahmani J. Vaccines and drug therapies to lock down novel coronavirus disease 2019 (COVID-19): a systematic review of clinical trials. Cureus. 2020;12:e8342.

[3] Abd El-Aziz TM, Stockand JD. Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2) - an update on the status of Infection, genetics and evolution: Journal of Molecular Epidemiology and Genetic in Infectious Diseases. 2020;83:104327.

[4] T. Alsalimi, L. Alsaidi, A. Alkhazr, M. Soufr, A. Altrom, A review of potential treatments to date in COVID-19 patients according to the stage of the disease, Current Research in Translational Medicine 66 (3) (2020) 93–104.

[5] WHO, Director-General’s Opening Remarks at the Media Briefing on COVID-19, 11 March 2020.

[6] Covian C, Retamal-Diaz A, Bueno SM, Kalergis AM. Could BCG vaccination induce protective trained immunity for SARS-CoV-2? Front. Immunol.. 2020;11:970.

[7] Ong E, Wong MU, Huffman A, He Y. COVID-19 Coronavirus Vaccine Design Using Reverse Vaccinology and Machine Learning. bioxiv; The Preprint Server for Biology. 2020.

[8] R. de Alwis, S. Chen, E.S. Gan, E.E. Ooi. Impact of immune enhancement on viral proteins, Viruses 12 (2020) .

[9] Amawi H, Abu Deiab GI, AA AA, Dua K, Tambuwala MM. COVID-19 pandemic: an overview of epidemiology, pathology, comprehensive and potential vaccines and therapeutics. Ther. Deliv.. 2020.11:245–6.

[10] Bourgonje AR, Abdulle AE, Timens W, Hillebrandts JL, Navis GJ, Gordijn SJ, et al. Angiotensin-converting enzyme 2 (ACE2) SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19). J. Pathol.. 2020.

[11] Albin M, Di Guardo G, Noonan JM, Lombardo M. The SARS-CoV-2 receptor, ACE-2, is expressed on many different cell types: implications for ACE-inhibitor- and angiotensin II receptor blocker-based cardiovascular therapies. Intern. Emerg. Med.. 2020.

[12] S.S. Al-Amri, A.T. Abbas, L.A. Siddig, A. Alghamdi, M.A. Sanki, M.K. Al-Muhanna, et al., Immunogenicity of candidate MERS-CoV DNA vaccines based on the spike protein, Sci. Rep. 7 (2017), 44075.

[13] R.L. Roper, K.E. Rehn, SARS vaccines: where are we? Expert Review of Vaccines 8 (2009) 878–898.

[14] Y.K. Cheng, S.C. Cheng, F.W. Sin, K.T. Chan, Y. Xie. Induction of T-cell response by a DNA vaccine encoding a novel HLA-A*0201 severe acute respiratory syndrome coronavirus epitope, Vaccine 25 (2007) 6070–6077.

[15] K. Muthumani, D. Faltarzino, E.L. Reuschel, C. Tingey, S. Flingai, D.O. Villarreal, et al., A synthetic consensus anti-spik protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates, Sci. Transl. Med. 7 (2015), 301ra132.

[16] K. Modjarrad, MERS-CoV vaccine candidates in development: the current landscape, Vaccine 34 (2016) 2962–2967.

[17] K. Modjarrad, C.C. Roberts, K.T. Mills, A.R. Castellano, K. Paolino, K. Muthumani, et al., Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial, Lancet Infect. Dis. 19 (2019) 913–1022.

[18] L.K. Yoon, J.H. Kim, First clinical trial of a MERS coronavirus DNA vaccine, Lancet Infect. Dis. 19 (2019) 924–925.

[19] H. Marcotte, L. Hannamström, Passive immunization toward magic bullets, Front. Immunol.. 2020 (2020), 1433–1434.

[20] F.R. Homburger, Maternally-derived passive immunity to enterotropic mouse hepatitis virus, Arch. Virol. 122 (1992) 133–141.

[21] Kang H, Wang Y, Tong Z, Liu X. Retest positive for SARS-CoV-2 RNA of ‘recovered’ patients with COVID-19: persistence, sampling issues, or reinfection? J. Med. Virol.. 2020.

[22] M. Ota, Will we see protection or reinfection in COVID-19? Nat. Rev. Immunol. 20 (2020) 351.

[23] Khuroo MS, Khuroo MS, Soфи, AA, Khuroo NS. COVID-19 vaccines: a race against time in the middle of death and devastation! Journal of clinical and experimental hepatology. 2020.

[24] R.L. Graham, E.F. Donaldson, R.S. Baric, A decade after SARS: strategies for controlling emerging coronaviruses, Nat. Rev. Microbiol. 11 (2013) 836–848.

[25] Yong CY, Ong HK, Yeap SK, Ho KL, Tan WS. Recent advances in the vaccine landscape, Vaccine 34 (2016) 2982–2987.

[26] A.S. Cockrell, R.S. Baric, An effective DNA vaccine platform for Middle East respiratory syndrome coronavirus (MERS-CoV): infection, immunological response, and vaccine development. J. Immunol. Res. 2019;2019:691738.

[27] A.S. Cockrell, R.S. Baric, An effective DNA vaccine platform for Middle East respiratory syndrome coronavirus, Annals of Translational Medicine 4 (2016) 499.

[28] A. Flemming. New vaccine platform? Nat. Rev. Drug Discov. 9 (2010) 191.

[29] Luzie N, Saville M, Harchett R, Halton J. Developing Covid-19 vaccines at pandemic speed. N. Engl. J. Med. 2020;382:1969–73.

[30] S. Linares-Fernandez, P.F. Rasquin, Vaccine development in the SARS-CoV-2 pandemic: a balancing act on accuracy and speed, International Journal of Public Health 65 (2020) 1433.

[31] M. Brise, S.M. Vrba, N. Kirk, Y. Liang, H. Ly. Emerging concepts and technologies in vaccine development for the SARS-CoV-2 pandemic, Immunol. 1 (2020) 580377.

[32] Mubarak A, Alturaiski W, Hemida MG. Middle East respiratory syndrome coronavirus (MERS-CoV): infection, immunological response, and vaccine development. J. Biol. Med. 2020;12:e6.

[33] A.S. Cockrell, R.S. Baric, An effective DNA vaccine platform for Middle East respiratory syndrome coronavirus, Annals of Translational Medicine 4 (2016) 499.

[34] J.A. Wolff, R.W. Malone, P. Williams, W. Chong, G. Asadi, A. Jani, et al., Direct gene transfer into mouse muscle in vivo, Science 247 (1990) 1465–1468.

[35] M.M. Silveira et al. [101].
A.J. Geall, A. Verma, G.R. Otten, C.A. Shaw, A. Hekele, K. Banerjee, et al., Corbett KS, Edwards D, Leist SR, Abiona OM, Boyoglu-Barnum S, Gillespie RA, J. Liu, R. Kjeken, I. Mathiesen, D.H. Barouch, Recruitment of antigen-presenting cells to the site of inoculation and augmentation of human immunodeficiency virus type 1 DNA vaccine immunogenicity by in vivo electroporation, J. Virol. 82 (2008) 5643–5649.

Z. Yu, Z. Huang, C. Sao, Y. Huang, F. Zhang, G. Ma, et al., Oral immunization of mouse using Bifidobacterium longum expressing VP1 protein from enterovirus 71, Arch. Virol. 158 (2013) 1071–1077.

J.M. Saavedra, N.A. Bauman, I. Oung, J.A. Pernan, R.H. Yolken, Feeding of Bifidobacterium bifidum and Streptococcus thermophilus to infants in hospital for prevention of diarrhoea and shedding of rotavirus, Lancet 344 (1994) 1046–1049.

S. Takei, C. Omo, K. Kitagawa, N. Morishita, T. Katayama, K. Shigemura, et al., Oral administration of genetically modified Bifidobacterium displaying HCV-NS5-specific systemic immune response in mice, Vaccine 32 (2014) 3066–3074.

T. Shirakawa, K. Kitagawa, Antitumor effect of oral cancer vaccine with Bifidobacterium delivering WT1 protein to gut immune system is superior to WT1 peptide vaccine, Hum Vaccin Immunother 14 (2018) 159–162.

Verbeke R, Lentacker I, De Smedt S, Dewitte H. Three decades of messenger RNA technology : an official journal of Bharati Vidyapeeth's Institute of Computer Applications and Management. 2020:1–7.

Ceylan RF, Ozkan B, Mulazimogullari E. Historical evidence for economic effects of COVID-19. The European Journal of Health Economics : HEPC : Health Economics in Prevention and Care. 2020:21:817–23.

Alam A, Siddiqui MF, Imam N, Ali R, Mustaque M, Ihsrat R. Covid-19: current knowledge, disease potential, prevention and clinical advances. Turkish journal of biology = Turk biyoloji dergisi. 2020;44:121–31.

Yamin M. Counting the cost of COVID-19. International journal of information technology : an official journal of Bharati Vidyapeeth's Institute of Computer Applications and Management. 2020:1–7.

E. Jamrozik, M.J. Selgelid, COVID-19 human challenge studies: ethical issues, Lancet Infect. Dis. 35 (2020) 43–49.

To KK, Hung IF, Ip JD, Ho WY, Poon LL, Peiris JS, et al., An immunoinformatics-derived DNA vaccine encoding human class II T cell epitopes of Ebola virus, Sudan virus, and Venezuelan equine encephalitis virus is immunogenic in HLA transgenic mice, Hum Vaccin Immunother 11 (2015) 2322–2328.

C.E. Bounds, P.E. Terry, L. Moise, D. Hannaman, W.D. Martin, A.S. De Groot, et al., An immunoinformatics-derived DNA vaccine encoding human class II T cell epitopes of Ebola virus, Sudan virus, and Venezuelan equine encephalitis virus is immunogenic in HLA transgenic mice, Hum Vaccin Immunother 11 (2015) 2322–2328.

Grifoni A, Sidney J, Zhang Y, Schesерamm RH, Peters B, Sette A. A sequence homology and Bioinformatic approach can predict candidate targets for immune responses to SARS-CoV-2. Cell Host Microbe 2020;27:671–80 e2.

X. Tian, C. Li, A. Huang, S. Xia, S. Lu, Z. Shi, et al., Potential binding of 2019 novel coronavirus spike protein spike by a SARS coronavirus-specific human monoclonal antibody, Emerging Microbes & Infections 9 (2020) 382–385.

Enayathkhani M, Hasanianzad M, Faesi S, Gokhani H, Davoodian P, Abhami N, et al. Reverse vaccinology approach to design a novel multi-epitope vaccine candidate against COVID-19: an in silico study. J. Biomed. Struct. Dyn.. 2020:1–16.

J Yu, LH Tontakoski, L. Peter, NB Mercado, K. McMahan, SH Mahlokhian, et al., DNA vaccine protection against SARS-CoV-2 in rhesus macaques, Science 369 (2020) 806–811.

The promise of mRNA vaccines: a biotech and industrial perspective, npj Vaccines 5 (2020) .

Verbeke R, Lentacker I, De Smedt S, Dewitte H. Three decades of messenger RNA vaccine development. Nano Today 2019:100766.

N. Jackson, K. Kester, D. Casimiro, S. Gurunathan, F. DeRosa, The promise of mRNA vaccines: a biotech and industrial perspective, npg Vaccines 5 (2020).

N. Pardi, M.J. Hogan, F.W. Porter, D. Weissman, mRNA vaccines - a new era in vaccinology, Nat. Rev. Drug Discov. 17 (2018) 261–279.

Verbeke R, Lentacker I, De Smedt S, Dewitte H. Three decades of messenger RNA vaccine development. Nano Today 2019:100766.

N. Jackson, K. Kester, D. Casimiro, S. Gurunathan, F. DeRosa, The promise of mRNA vaccines: a biotech and industrial perspective, npg Vaccines 5 (2020).

N. Pardi, M.J. Hogan, F.W. Porter, D. Weissman, mRNA vaccines - a new era in vaccinology, Nat. Rev. Drug Discov. 17 (2018) 261–279.

Rauch S, Janey F, Schmidt KE, Petch B. New vaccine technologies to combat outbreak situations. Front. Immunol.. 2018;9:1963.

H.L. Shih, C.J. Wu, Y.F. Tu, C.Y. Chi, Fighting COVID-19: a quick review of diagnoses, therapies, and vaccines, Biom. J. 43 (4) (2020) 341–354.

Zhang C, Maruggi G, Shan H, Li J. Advances in mRNA vaccines for infectious diseases. Front. Immunol.. 2018;9:1654.

R. Chakraborty, S. Parvez, COVID-19: an overview of the current pharmacological interventions, vaccines, and clinical trials, Biochem. Pharmacol. 180 (2020), 114184.

P.C. Eaglezou, C. Sapet, T. Demoulins, P. Milona, T. Ebens, K. Schulze, et al., Self-amplifying replicon RNA delivery to dendritic cells by cationic lipids, Molecular therapy Nucleic Acids 12 (2018) 118–134.

A.J. Geall, A. Verma, R.G. Otten, C.A. Shaw, A. Hekele, K. Banerjee, et al., Nonviral delivery of self-amplifying RNA vaccines, Proc. Natl. Acad. Sci. U. S. A. 109 (2012) 14604–14609.

Corbett KS, Edwards D, Leit SR, Abiona OM, Boyoglu-Barnum S, Gillespie RA, et al. SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen PathogenPreparedness. bioRxiv : The Preprint Server for Biology. 2020.

A. Koizila, Y.J. Joo, A. Khatami, C. Chiu, P.N. Britton, Vaccines for COVID-19: the current state of play, Paediatr. Respir. Rev. 35 (2020) 43–49.

Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makheke M, Coler RN, et al., An mRNA vaccine against SARS-CoV-2 - preliminary report. N. Engl. J. Med.. 2020.

M. Mulligan, K. Lyke, N. Kitchin, J. Alsbasha, A. Gurtman, S. Lockhart, et al., Phase 1/2 Study to Describe the Safety and Immunogenicity of a COVID-19 DNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim Report, 2020.

S.C. Pandey, V. Pande, D. Satl, S. Upreti, M. Samant, Vaccination strategies to combat novel coronavirus SARS-CoV-2, Life Sci. 256 (2020), 117956.

L. Moise, J.A. McMurry, S. Buus, S. Frey, W.D. Martin, A.S. De Groot, In silico- accelerated identification of conserved and immunogenic varicella/vaccinia T-cell epitopes, Vaccine 27 (2009) 6471–6479.

C.S. Eickhoff, D. Van Aartsen, P.E. Terry, S.K. Meymandi, M.M. Traina, S. Hernandez, et al., An immunoinformatic approach for identification of Trypanosoma cruzi HLA-A2-restricted CD8(+) T cell epitopes, Hum Vaccin Immunother 11 (2015) 2322–2328.